Literature DB >> 25924571

Drug developers reboot anti-NGF pain programmes.

Asher Mullard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25924571     DOI： 10.1038/nrd4612

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  Anti-NGF painkillers back on track?

Authors:  David Holmes
Journal:  Nat Rev Drug Discov       Date:  2012-04-30       Impact factor: 84.694
  1 in total
  12 in total

1.  Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain.

Authors:  Shouan Zhu; Jianxi Zhu; Gehua Zhen; Yihe Hu; Senbo An; Yusheng Li; Qin Zheng; Zhiyong Chen; Ya Yang; Mei Wan; Richard Leroy Skolasky; Yong Cao; Tianding Wu; Bo Gao; Mi Yang; Manman Gao; Julia Kuliwaba; Shuangfei Ni; Lei Wang; Chuanlong Wu; David Findlay; Holger K Eltzschig; Hong Wei Ouyang; Janet Crane; Feng-Quan Zhou; Yun Guan; Xinzhong Dong; Xu Cao
Journal:  J Clin Invest       Date:  2019-02-04       Impact factor: 14.808

Review 2.  Combining Human and Rodent Genetics to Identify New Analgesics.

Authors:  Alban Latremoliere; Michael Costigan
Journal:  Neurosci Bull       Date:  2017-07-01       Impact factor: 5.203

3.  Outlook for NGF inhibitor painkiller class brightens.

Authors:  Kelly Rae Chi
Journal:  Nat Biotechnol       Date:  2016-07-12       Impact factor: 54.908

Review 4.  What is new in pain modification in osteoarthritis?

Authors:  Rachel E Miller; Joel A Block; Anne-Marie Malfait
Journal:  Rheumatology (Oxford)       Date:  2018-05-01       Impact factor: 7.580

Review 5.  Pharmacological Treatment of Pain in Osteoarthritis: A Descriptive Review.

Authors:  Muhammad Hassan Majeed; Syed Ali Amir Sherazi; Douglas Bacon; Zahid H Bajwa
Journal:  Curr Rheumatol Rep       Date:  2018-11-21       Impact factor: 4.592

Review 6.  Targeting neurotrophic factors: Novel approaches to musculoskeletal pain.

Authors:  Anne-Marie Malfait; Rachel E Miller; Joel A Block
Journal:  Pharmacol Ther       Date:  2020-04-18       Impact factor: 12.310

7.  Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of Pancreatic Ductal Adenocarcinoma.

Authors:  Jami L Saloman; Aatur D Singhi; Douglas J Hartman; Daniel P Normolle; Kathryn M Albers; Brian M Davis
Journal:  Pancreas       Date:  2018-08       Impact factor: 3.327

Review 8.  Nerve growth factor: a neuroimmune crosstalk mediator for all seasons.

Authors:  Stephen D Skaper
Journal:  Immunology       Date:  2017-02-21       Impact factor: 7.397

Review 9.  Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?

Authors:  Rachel E Miller; Joel A Block; Anne-Marie Malfait
Journal:  Curr Opin Rheumatol       Date:  2017-01       Impact factor: 5.006

Review 10.  Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.

Authors:  Rachel E Miller; Anne-Marie Malfait; Joel A Block
Journal:  Clin Exp Rheumatol       Date:  2017-09-28       Impact factor: 4.473
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.